Published in Cancer on December 15, 1989
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59
Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J Clin Microbiol (1993) 2.49
Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38
Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med (1973) 2.30
Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med (1969) 2.13
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88
Data elements for emergency department systems, release 1.0 (DEEDS): a summary report. DEEDS Writing Committee. Ann Emerg Med (1998) 1.86
Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med (1973) 1.83
Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol (1994) 1.79
Pseudohyperkalemia due to release of potassium from white blood cells during clotting. N Engl J Med (1966) 1.73
Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis (2000) 1.72
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
The pulmonary toxicity of antineoplastic agents. Semin Oncol (1982) 1.65
Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J Clin Oncol (1993) 1.64
Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res (1966) 1.62
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Recovery of cytomegalovirus from adults with neoplastic disease. Ann Intern Med (1966) 1.58
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol (1989) 1.56
Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol (1993) 1.55
Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) (1987) 1.50
Socioeconomic status and cancer survival. J Clin Oncol (1991) 1.48
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am (2006) 1.38
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA (1966) 1.34
Cancer treatment and age: patient perspectives. J Natl Cancer Inst (1993) 1.34
Special report. Steriod receptors in breast cancer. N Engl J Med (1979) 1.33
Enhancement of the antitumor effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A. J Natl Cancer Inst (1972) 1.32
Treatment of Burkitt's tumor with cyclophosphamide. Cancer (1970) 1.29
Chemotherapy of brain tumors. Arch Neurol (1977) 1.29
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
Cost effective Internet access and video conferencing for a community cancer network. Proc Annu Symp Comput Appl Med Care (1995) 1.28
In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst (1971) 1.27
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood (1968) 1.26
Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25
Comparison of BACTEC Plus 26 and 27 media with and without fastidious organism supplement with conventional methods for culture of sterile body fluids. J Clin Microbiol (1994) 1.25
Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med (1967) 1.25
Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother (2001) 1.24
Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology (1989) 1.21
Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer (1979) 1.18
Preoperative and follow-up procedures on patients with breast cancer. Cancer (1980) 1.17
Evaluation of BACTEC MYCO/F Lytic medium for recovery of mycobacteria, fungi, and bacteria from blood. J Clin Microbiol (2001) 1.16
Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res (1968) 1.16
Central nervous system involvement in Burkitt's lymphoma. Blood (1970) 1.16
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
The health consequences of smoking. Cancer. Med Clin North Am (1992) 1.15
Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep (1985) 1.15
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer (1983) 1.14
Intestinal and pulmonary cryptosporidiosis in an infant with severe combined immune deficiency. J Pediatr Gastroenterol Nutr (1984) 1.14
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood (1971) 1.14
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13
Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res (1980) 1.13
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res (1991) 1.13
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer (1978) 1.13
A lesson from the mammography issue. Ann Intern Med (1978) 1.11
Lymphoma of the breast. Ann Surg (1981) 1.11
Comparison of BACTEC plus Aerobic/F, Anaerobic/F, Peds Plus/F, and Lytic/F media with and without fastidious organism supplement to conventional methods for culture of sterile body fluids. Diagn Microbiol Infect Dis (1997) 1.10
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res (1965) 1.08
Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages. Am J Respir Cell Mol Biol (1997) 1.08
Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med (1967) 1.07
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol (1996) 1.07
Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res (1973) 1.07
Acetohydroxamate: bacterial urease inhibitor with therapeutic potential in hyperammonaemic states. Nature (1965) 1.07
Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep (1979) 1.07
The implementation of telemedicine within a community cancer network. J Am Med Inform Assoc (1997) 1.07
Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res (1979) 1.05
Serum immune globulin concentrations in acute leukemia during intensive chemotherapy. Cancer (1965) 1.03
Cell wall studies of Histoplasma capsulatum and Blastomyces dermatitidis using autologous and heterologous enzymes. Infect Immun (1977) 1.03
Plasma thyroid-stimulating hormone and thyroxine concentrations in breast cancer. Cancer (1978) 1.01
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res (1989) 1.01
The Philadelphia chromosome and chronic myelogenous leukemia. J Natl Cancer Inst (1966) 1.00
Neoplasms of the large bowel following ureterosigmoidostomy. Arch Surg (1977) 0.99
A study of cyclophosphamide, adriamycin, cis-platinum, and methotrexate in advanced transitional cell carcinoma of the urinary tract. Cancer (1983) 0.99
NIH clinical staff conference. Burkitt's tumor. Ann Intern Med (1969) 0.98
Plasma cell myeloma with D-myeloma protein (IgD myeloma). Am J Med (1968) 0.98
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer (1987) 0.97
Serum alpha-fetoprotein in 184 Ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations. Cancer (1974) 0.97
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer (1978) 0.97
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment. Cancer (1972) 0.96
Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. Cancer Res (1988) 0.96
The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer (1987) 0.95
Training program in medical oncology. Ann Intern Med (1973) 0.95
A controlled trial of urethane treatment in multiple myeloma. Blood (1966) 0.95
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest (1992) 0.95